Monoclonal antibodyPhase 3 trialInvestigational
Nivolumab + Ipilimumab
How it works
Blocks PD-1 and CTLA-4, proteins on immune cells that normally help prevent overactive immune responses, allowing the immune system to attack cancer cells.
Cancer types
Melanoma— All patients
Efficacy
In clinical trials, around 50% of patients achieved an objective response, with a median overall survival of approximately 11 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.